Pipeline

Celgene invests significant resources into creating disease-altering therapies for cancers. Hundreds of clinical studies around the world use our innovative treatments.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Reset Filter

Advanced Search

Collapse Advanced Search

Disease Areas:
  • Clear
Phase:
  • Clear
Molecules:
  • Clear

Pipeline by Disease

Current as of 4/01/2017

Acute Myeloid Leukemia

Show Hide

AG-881 (Pan-IDH Inhibitor)a

  • Phase 1 Acute Myeloid Leukemia
Additional Information
Molecule Overview

View more information about AG-881.

Clinical Trials

Search Celgene-sponsored and collaborator AG-881 clinical trials in Acute Myeloid Leukemia

  • a In collaboration with Agios Pharmaceuticals, Inc.

Azacitidine (DNA Methyltransferase Inhibitor)

  • Post Approval Research Acute Myeloid Leukemia AML (20%-30% blasts) (EU)
  • Post Approval Research Acute Myeloid Leukemia AML (>30% blasts) (EU)
Additional Information
Molecule Overview

View more information about Azacitidine.

Clinical Trials

Search Celgene-sponsored and collaborator Azacitidine clinical trials in Acute Myeloid Leukemia

CC-486 (DNA Methyltransferase Inhibitor)

  • Phase 3 Acute Myeloid Leukemia Post-induction AML maintenance
Additional Information
Molecule Overview

View more information about CC-486.

Clinical Trials

Search Celgene-sponsored and collaborator CC-486 clinical trials in Acute Myeloid Leukemia

CC-90002 (Anti-CD47 Antibody)

  • Phase 1 Acute Myeloid Leukemia
Additional Information
Molecule Overview

View more information about CC-90002.

Clinical Trials

Search Celgene-sponsored and collaborator CC-90002 clinical trials in Acute Myeloid Leukemia

CC-90009

  • Phase 1 Acute Myeloid Leukemia
Additional Information
Clinical Trials

Search Celgene-sponsored and collaborator CC-90009 clinical trials in Acute Myeloid Leukemia

Durvalumab (PD-L1 Inhibitor)a

  • Phase 2 Acute Myeloid Leukemia
Additional Information
Molecule Overview

View more information about Durvalumab.

Clinical Trials

Search Celgene-sponsored and collaborator Durvalumab clinical trials in Acute Myeloid Leukemia

  • a In collaboration with MedImmune Limited, a wholly owned subsidiary of AstraZeneca PLC

Enasidenib

  • Post Approval Research Acute Myeloid Leukemia Relapsed/refractory IDH2 mutationa
Additional Information
Molecule Overview

View more information about Enasidenib.

Clinical Trials

Search Celgene-sponsored and collaborator Enasidenib clinical trials in Acute Myeloid Leukemia

  • a In collaboration with Agios Pharmaceuticals, Inc.

PNK-007

  • Phase 1 Acute Myeloid Leukemia
Additional Information
Clinical Trials

Search Celgene-sponsored and collaborator PNK-007 clinical trials in Acute Myeloid Leukemia

Beta-thalassemia

Show Hide

Luspatercept (Modified Activin Receptor Type IIB Fusion Protein)a

  • Phase 3 Beta-thalassemia
Additional Information
Molecule Overview

View more information about Luspatercept.

Clinical Trials

Search Celgene-sponsored and collaborator Luspatercept clinical trials in Beta-thalassemia

  • a In collaboration with Acceleron Pharma Inc.

Breast Cancer

Show Hide

CC-486 (DNA Methyltransferase Inhibitor)

  • Phase 2 Breast Cancer Metastatic
Additional Information
Molecule Overview

View more information about CC-486.

Clinical Trials

Search Celgene-sponsored and collaborator CC-486 clinical trials in Breast Cancer

nab-Paclitaxel (Albumin-Bound Microtuble Inhibitor)

  • Post Approval Research Breast Cancer Metastatic
Additional Information
Molecule Overview

View more information about nab-Paclitaxel.

Clinical Trials

Search Celgene-sponsored and collaborator nab-Paclitaxel clinical trials in Breast Cancer

Chronic Lymphocytic Leukemia

Show Hide

CC-122

  • Phase 1 Chronic Lymphocytic Leukemia
Additional Information
Molecule Overview

View more information about CC-122.

Clinical Trials

Search Celgene-sponsored and collaborator CC-122 clinical trials in Chronic Lymphocytic Leukemia

Durvalumab (PD-L1 Inhibitor)a

  • Phase 1 Chronic Lymphocytic Leukemia
Additional Information
Molecule Overview

View more information about Durvalumab.

Clinical Trials

Search Celgene-sponsored and collaborator Durvalumab clinical trials in Chronic Lymphocytic Leukemia

  • a In collaboration with MedImmune Limited, a wholly owned subsidiary of AstraZeneca PLC

Lung Cancer

Show Hide

CC-486 (DNA Methyltransferase Inhibitor)

  • Phase 2 Lung Cancer Non-small cell lung: Advanced
Additional Information
Molecule Overview

View more information about CC-486.

Clinical Trials

Search Celgene-sponsored and collaborator CC-486 clinical trials in Lung Cancer

nab-Paclitaxel (Albumin-Bound Microtuble Inhibitor)

  • Post Approval Research Lung Cancer Non-small cell lung: Advanced (first-line)
Additional Information
Molecule Overview

View more information about nab-Paclitaxel.

Clinical Trials

Search Celgene-sponsored and collaborator nab-Paclitaxel clinical trials in Lung Cancer

Lymphoma

Show Hide

CC-122

  • Phase 1 Lymphoma Diffuse large B-cell lymphoma
  • Phase 1 Lymphoma Indolent lymphoma: Relapsed/refractory
Additional Information
Molecule Overview

View more information about CC-122.

Clinical Trials

Search Celgene-sponsored and collaborator CC-122 clinical trials in Lymphoma

CC-486 (DNA Methyltransferase Inhibitor)

  • Phase 1 Lymphoma Diffuse large B-cell lymphoma
Additional Information
Molecule Overview

View more information about CC-486.

Clinical Trials

Search Celgene-sponsored and collaborator CC-486 clinical trials in Lymphoma

CC-90002 (Anti-CD47 Antibody)

  • Phase 1 Lymphoma Non-Hodgkin lymphoma (NHL)
Additional Information
Molecule Overview

View more information about CC-90002.

Clinical Trials

Search Celgene-sponsored and collaborator CC-90002 clinical trials in Lymphoma

Durvalumab (PD-L1 Inhibitor)a

  • Phase 1 Lymphoma Non-Hodgkin lymphoma (NHL)
Additional Information
Molecule Overview

View more information about Durvalumab.

Clinical Trials

Search Celgene-sponsored and collaborator Durvalumab clinical trials in Lymphoma

  • a In collaboration with MedImmune Limited, a wholly owned subsidiary of AstraZeneca PLC

JCAR017 (CD19 CAR-T)a

  • Phase 1 Lymphoma Agressive large B-cell lymphoma: Relapsed/refractory
Additional Information
Clinical Trials

Search Celgene-sponsored and collaborator JCAR017 (CD19 CAR-T) clinical trials in Lymphoma

  • a In collaboration with Juno Therapeutics. Celgene has commercial rights outside of North America and China.

Lenalidomide (IMiD® Agent)

  • Post Approval Research Lymphoma Mantle cell lymphoma: Relapsed/refractory (US)
  • Post Approval Research Lymphoma Mantle cell lymphoma: Relapsed/refractory (EU)
  • Phase 3 Lymphoma Diffuse large B-cell (ABC-subtype): First-line
  • Phase 3 Lymphoma Indolent lymphoma: Relapsed/refractory
  • Phase 3 Lymphoma Follicular lymphoma: First-line
  • Post Approval Research Lymphoma Adult T-cell leukemia-lymphoma (Japan)
Additional Information
Molecule Overview

View more information about Lenalidomide.

Clinical Trials

Search Celgene-sponsored and collaborator Lenalidomide clinical trials in Lymphoma

Romidepsin (Histone Deacetylase Inhibitor)

  • Post Approval Research Lymphoma Cutaneous T-cell lymphoma (US)a
  • Post Approval Research Lymphoma Peripheral T-cell lymphoma: Relapsed/refractoryb
  • Phase 3 Lymphoma Peripheral T-cell lymphoma: First-line
Additional Information
Molecule Overview

View more information about Romidepsin.

Clinical Trials

Search Celgene-sponsored and collaborator Romidepsin clinical trials in Lymphoma

  • a Filing for regulatory approval based on pivotal phase II data.
  • b Filing for regulatory approval based on pivotal phase II data.

Multiple Myeloma

Show Hide

CC-122

  • Phase 1 Multiple Myeloma
Additional Information
Molecule Overview

View more information about CC-122.

Clinical Trials

Search Celgene-sponsored and collaborator CC-122 clinical trials in Multiple Myeloma

CC-220

  • Phase 1 Multiple Myeloma Relapsed/refractory
Additional Information
Clinical Trials

Search Celgene-sponsored and collaborator CC-220 clinical trials in Multiple Myeloma

Citarinostat (ACY-241)

  • Phase 1 Multiple Myeloma Relapsed/refractory
Additional Information
Clinical Trials

Search Celgene-sponsored and collaborator Citarinostat (ACY-241) clinical trials in Multiple Myeloma

Durvalumab (PD-L1 Inhibitor)a

  • Phase 1 Multiple Myeloma Relapsed/refractory, Newly diagnosed
Additional Information
Molecule Overview

View more information about Durvalumab.

Clinical Trials

Search Celgene-sponsored and collaborator Durvalumab clinical trials in Multiple Myeloma

  • a In collaboration with MedImmune Limited, a wholly owned subsidiary of AstraZeneca PLC

Lenalidomide (IMiD® Agent)

  • Post Approval Research Multiple Myeloma Relapsed/refractory
  • Post Approval Research Multiple Myeloma Newly diagnosed
  • Post Approval Research Multiple Myeloma Maintenance
Additional Information
Molecule Overview

View more information about Lenalidomide.

Clinical Trials

Search Celgene-sponsored and collaborator Lenalidomide clinical trials in Multiple Myeloma

PNK-007

  • Phase 1 Multiple Myeloma
Additional Information
Clinical Trials

Search Celgene-sponsored and collaborator PNK-007 clinical trials in Multiple Myeloma

Pomalidomide (IMiD® Agent)

  • Post Approval Research Multiple Myeloma Relapsed/refractory
Additional Information
Molecule Overview

View more information about Pomalidomide.

Clinical Trials

Search Celgene-sponsored and collaborator Pomalidomide clinical trials in Multiple Myeloma

Thalidomide

  • Post Approval Research Multiple Myeloma Newly Diagnosed
Additional Information
Clinical Trials

Search Celgene-sponsored and collaborator Thalidomide clinical trials in Multiple Myeloma

bb2121 (BCMA CAR-T)a

  • Phase 1 Multiple Myeloma
Additional Information
Clinical Trials

Search Celgene-sponsored and collaborator bb2121 (BCMA CAR-T) clinical trials in Multiple Myeloma

  • a In collaboration with bluebird bio, Inc.

Myelofibrosis

Show Hide

Luspatercept (Modified Activin Receptor Type IIB Fusion Protein)a

  • Phase 2 Myelofibrosis
Additional Information
Molecule Overview

View more information about Luspatercept.

Clinical Trials

Search Celgene-sponsored and collaborator Luspatercept clinical trials in Myelofibrosis

  • a In collaboration with Acceleron Pharma Inc.

Myelodysplastic Syndromes

Show Hide

Azacitidine (DNA Methyltransferase Inhibitor)

  • Post Approval Research Myelodysplastic Syndromes
Additional Information
Molecule Overview

View more information about Azacitidine.

Clinical Trials

Search Celgene-sponsored and collaborator Azacitidine clinical trials in Myelodysplastic Syndromes

CC-486 (DNA Methyltransferase Inhibitor)

  • Phase 3 Myelodysplastic Syndromes Lower-risk
  • Phase 2 Myelodysplastic Syndromes Post hypomethylating agent (HMA) failure
Additional Information
Molecule Overview

View more information about CC-486.

Clinical Trials

Search Celgene-sponsored and collaborator CC-486 clinical trials in Myelodysplastic Syndromes

CC-90002 (Anti-CD47 Antibody)

  • Phase 1 Myelodysplastic Syndromes
Additional Information
Molecule Overview

View more information about CC-90002.

Clinical Trials

Search Celgene-sponsored and collaborator CC-90002 clinical trials in Myelodysplastic Syndromes

Durvalumab (PD-L1 Inhibitor)a

  • Phase 2 Myelodysplastic Syndromes Post HMA failure
Additional Information
Molecule Overview

View more information about Durvalumab.

Clinical Trials

Search Celgene-sponsored and collaborator Durvalumab clinical trials in Myelodysplastic Syndromes

  • a In collaboration with MedImmune Limited, a wholly owned subsidiary of AstraZeneca PLC

Lenalidomide (IMiD® Agent)

  • Post Approval Research Myelodysplastic Syndromes Deletion 5q
Additional Information
Molecule Overview

View more information about Lenalidomide.

Clinical Trials

Search Celgene-sponsored and collaborator Lenalidomide clinical trials in Myelodysplastic Syndromes

Luspatercept (Modified Activin Receptor Type IIB Fusion Protein)a

  • Phase 3 Myelodysplastic Syndromes
Additional Information
Molecule Overview

View more information about Luspatercept.

Clinical Trials

Search Celgene-sponsored and collaborator Luspatercept clinical trials in Myelodysplastic Syndromes

  • a In collaboration with Acceleron Pharma Inc.

Pancreatic Cancer

Show Hide

nab-Paclitaxel (Albumin-Bound Microtuble Inhibitor)

  • Post Approval Research Pancreatic Cancer Pancreatic: Metastatic (first-line)
  • Phase 3 Pancreatic Cancer Pancreatic: Adjuvant
Additional Information
Molecule Overview

View more information about nab-Paclitaxel.

Clinical Trials

Search Celgene-sponsored and collaborator nab-Paclitaxel clinical trials in Pancreatic Cancer

Solid Tumors

Show Hide

CC-122

  • Phase 1 Solid Tumors Hepatocellular carcinoma
Additional Information
Molecule Overview

View more information about CC-122.

Clinical Trials

Search Celgene-sponsored and collaborator CC-122 clinical trials in Solid Tumors

CC-90002 (Anti-CD47 Antibody)

  • Phase 1 Solid Tumors
Additional Information
Molecule Overview

View more information about CC-90002.

Clinical Trials

Search Celgene-sponsored and collaborator CC-90002 clinical trials in Solid Tumors

CC-90011 (LSD1 Inhibitor)

  • Phase 1 Solid Tumors
Additional Information
Clinical Trials

Search Celgene-sponsored and collaborator CC-90011 clinical trials in Solid Tumors

Marizomib (Proteasome Inhibitor)

  • Phase 2 Solid Tumors Glioblastoma
Additional Information
Molecule Overview

View more information about Marizomib.

Clinical Trials

Search Celgene-sponsored and collaborator Marizomib clinical trials in Solid Tumors

nab-Paclitaxel (Albumin-Bound Microtuble Inhibitor)

  • Post Approval Research Solid Tumors Gastric: Metastatic (Japan)a
Additional Information
Molecule Overview

View more information about nab-Paclitaxel.

Clinical Trials

Search Celgene-sponsored and collaborator nab-Paclitaxel clinical trials in Solid Tumors

  • a Trial conducted by licensee partner, Taiho Pharmaceuticals Co. Ltd.